Evidence map›Paper›PMID 24642450›Full record

Trial reportJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2015

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.

Jill M Kolesar, Marcia Pomplun, Tom Havighurst, Jeanne Stublaski, Barbara Wollmer, KyungMann Kim, Joseph A Tangrea, Howard L Parnes, Margaret G House, Jason Gee and 2 more

Open access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jill M KolesarSchool of Pharmacy, University of Wisconsin, Madison, WI, USA Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA jmkolesar@pharmacy.wisc.edu.
Marcia PomplunCarbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA.
Tom HavighurstCarbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
Jeanne StublaskiCarbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA.
Barbara WollmerCarbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA.
KyungMann KimCarbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.
Joseph A TangreaDivision of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Howard L ParnesDivision of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Margaret G HouseDivision of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Jason GeeInstitute of Urology, Lahey Clinic Medical Center, Burlington, MA, USA.
Edward MessingUniversity of Rochester Medical Center, Rochester, NY, USA.
Howard H BaileyCarbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
University of Wisconsin–Madison · USNational Cancer Institute · USUniversity of Wisconsin Carbone Cancer Center · USLahey Hospital and Medical Center · USUniversity of Rochester Medical Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
ZOSUQUIDAR TRIHYDROCHLORIDE IN NEWLY DIAGNOSED AMLM01RR003186 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 1986 to 2007
$19.3M
PHASE 1 AND PHASE 2 CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS -261035153N01CN035153 · CN · UNIVERSITY OF WISCONSIN - MAD · PI BAILEY, HOWARD H. · 2004 to 2006
–
NCI NIH HHS N01 CN035153NCI NIH HHS N01-CN-35153-6NCI NIH HHS P30 CA014520NCRR NIH HHS M01 RR003186NCRR NIH HHS M01 RR03186
6 · The paper itself

Abstract

backgroundThe isoflavone genistein, a natural soy product with receptor tyrosine kinase-inhibiting activity, as well as phytoestrogenic and other potential anticarcinogenic effects, is being studied as an anticancer agent. Since isoflavones are commonly consumed in food products containing soy proteins, a method to control for baseline isoflavone consumption is needed.

methodsHPLC was used to evaluate baseline plasma and urine concentrations of isoflavone in fifty-four participants with bladder cancer enrolled on a phase II chemoprevention study of G-2535. The soy food frequency questionnaire was used to assess participant's baseline soy intake. The association between baseline isoflavone concentrations and intakes for genistein and daidzein was assessed by the Spearman's rank correlation coefficient.

resultsThe majority of participants had no detectable genistein or daidzein in plasma at baseline. The median and range of values were 0 (0-1480) nmol/L for genistein, and 0 (0-1260) nmol/L for daidzein. In urine, the median and range of values were 91.0 (0-9030) nmol/L for genistein and 623 (0-100,000) nmol/L for daidzein. The median and range of weekly estimated genistein intake was 0 (0-236) mg/wk; the median and range of weekly estimated daidzein intake was 0 (0-114) mg/wk. There was no relationship to soy intake as measured by the food frequency questionnaire and baseline isoflavone levels in plasma or urine and the Spearman's rank correlation coefficients were not significant.

conclusionThe soy food frequency questionnaire did not correlate with plasma or urine concentrations of either isoflavone. IMPACT: Alternative methods for controlling for soy consumption, including measuring plasma and urine concentrations, in isoflavone chemoprevention trials should be considered.

Indexed as

Antineoplastic AgentsFeeding BehaviorGenisteinIsoflavonesSoy FoodsSurveys and QuestionnairesBiomarkersChromatography, High Pressure LiquidHumansPredictive Value of TestsUrinary Bladder NeoplasmsAntineoplastic AgentsBiomarkersdaidzeinGenisteinIsoflavoneschemopreventionisoflavonespharmacokineticsSoy food frequency questionnaire

Identifiers

PMID24642450
PMCPMC4261043
OpenAlexW2110827972

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.